We are live on ! Find out more
PTGX icon

Protagonist Therapeutics
PTGX

76 hedge funds and large institutions have $228M invested in Protagonist Therapeutics in 2019 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 29 increasing their positions, 18 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more funds holding in top 10

Funds holding in top 10: 1 → 3 (+2)

111% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 9

61% more repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 18

15% more funds holding

Funds holding: 66 → 76 (+10)

9% more capital invested

Capital invested by funds: $208M → $228M (+$19M)

1.54% less ownership

Funds ownership: 73.6% → 72.06% (-1.5%)

Holders
76
Holders Change
+10
Holders Change %
+15.15%
% of All Funds
1.67%
Holding in Top 10
3
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+200%
% of All Funds
0.07%
New
19
Increased
29
Reduced
18
Closed
9
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
RI
RTW Investments
New York
+$9.61M
2
NHAS
Novo Holdings A/S
Denmark
+$5.74M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$5.45M
4
BBA
Baker Bros. Advisors
New York
+$2.26M
5
Northern Trust
Northern Trust
Illinois
+$2.22M

Top Sellers

Rank Fund Capital Flow
1
BI
BVF Inc
California
-$4.8M
2
JP Morgan Chase
JP Morgan Chase
New York
-$3.49M
3
ACP
Acuta Capital Partners
California
-$3.19M
4
TCM
Tekla Capital Management
Massachusetts
-$1.47M
5
SSA
Schonfeld Strategic Advisors
New York
-$1.23M
Name Holding Trade Value Shares
Change 		Change in
Stake
Two Sigma Advisers
26
Two Sigma Advisers
New York
$1.83M +$343K +27,200 +22%
N
27
Nuveen
North Carolina
$1.81M +$1.41M +111,656 +287%
Morgan Stanley
28
Morgan Stanley
New York
$1.47M +$1.53M +121,347 +18,498%
Allianz Asset Management
29
Allianz Asset Management
Germany
$1.39M -$136K -10,814 -9%
BCM
30
Bridgeway Capital Management
Texas
$1.09M – – –
Squarepoint
31
Squarepoint
New York
$1.01M -$231K -18,303 -18%
Bank of New York Mellon
32
Bank of New York Mellon
New York
$930K -$336K -26,686 -26%
Russell Investments Group
33
Russell Investments Group
United Kingdom
$926K +$968K +76,835 New
Invesco
34
Invesco
Georgia
$764K -$267K -21,196 -25%
Two Sigma Investments
35
Two Sigma Investments
New York
$594K -$916K -72,703 -60%
BFM
36
Boothbay Fund Management
New York
$588K -$718K -56,993 -54%
Charles Schwab
37
Charles Schwab
California
$488K +$52.2K +4,145 +11%
Grantham, Mayo, Van Otterloo & Co (GMO)
38
Grantham, Mayo, Van Otterloo & Co (GMO)
Massachusetts
$461K +$484K +38,400 New
WG
39
Winton Group
United Kingdom
$446K +$468K +37,124 New
T. Rowe Price Associates
40
T. Rowe Price Associates
Maryland
$329K +$99.3K +7,879 +40%
California State Teachers Retirement System (CalSTRS)
41
California State Teachers Retirement System (CalSTRS)
California
$319K +$40.3K +3,195 +14%
TCM
42
Tuttle Capital Management
Connecticut
$313K +$303K +24,042 New
Wells Fargo
43
Wells Fargo
California
$312K +$68.3K +5,421 +26%
FSA
44
Franklin Street Advisors
North Carolina
$282K – – –
State of Wisconsin Investment Board
45
State of Wisconsin Investment Board
Wisconsin
$274K +$287K +22,800 New
AQR Capital Management
46
AQR Capital Management
Connecticut
$272K +$286K +22,687 New
CSS
47
Cubist Systematic Strategies
Connecticut
$264K +$277K +21,992 New
Deutsche Bank
48
Deutsche Bank
Germany
$241K -$316K -25,111 -55%
PP
49
PDT Partners
New York
$236K +$58.1K +4,610 +31%
FIM
50
Freedom Investment Management
Connecticut
$222K -$21.8K -1,733 -9%
1
2
3 4

PTGX Hedge Fund Activity: Q3 2019 in Review

76 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Protagonist Therapeutics (PTGX) for Q3 2019, worth a combined $228M — up 9.1% from $208M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new PTGX positions and 9 closed out — a net gain of 10 holders — while 29 added to existing stakes and 18 trimmed.

The largest buyer was RTW Investments, opening a new position worth an estimated $9.61M. The largest seller was BVF Inc, cutting an estimated $4.8M.

  • 76 institutional investors held Protagonist Therapeutics (PTGX) as of Q3 2019, up from 66 in Q2 2019.
  • Funds reported $228M of Protagonist Therapeutics stock for Q3 2019, up 9.1% quarter-over-quarter.
  • 19 funds opened new Protagonist Therapeutics positions in Q3 2019 and 9 closed out, a net change of +10 holders.
  • The largest Protagonist Therapeutics buyer in Q3 2019 was RTW Investments, an estimated $9.61M added.
  • The largest Protagonist Therapeutics seller in Q3 2019 was BVF Inc, an estimated $4.8M sold.

Based on aggregated 13F filings for Q3 2019.